Pathogenic T cell cytokines in multiple sclerosis.

J Exp Med · 2020 · PMC7037255 · PMID 31611252

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not quite achieve significanceno p-value reported

Consistent with this observation, a clinical trial assessing the efficacy of secukinumab, an IL-17A–neutralizing antibody, in patients with RRMS demonstrated a significant reduction in the number of cumulative new gadolinium-enhancing T1 lesions, although the reduction in the cumulative number of combined unique active lesions did not quite achieve significance ( Havrdová et al., 2016 ).

also in 27 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.